Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.51 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 7/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8488129 | 0.76 | EGFR (0.56) | APPGRM4EGFRKDRMAPK1 | |
| SCHEMBL28480411 | 0.76 | STK17B (0.54) | APPGRM4ABCG2EGFRKDR | |
| SCHEMBL2103491 | 0.76 | SYK (0.54) | APPGRM4ABCG2EGFRKDR | |
| SCHEMBL1392126 | 0.74 | APP (0.77) | APPGRM4CA12CA1CA2 | |
| SCHEMBL20680404 | 0.74 | EGFR (0.52) | APPGRM4ABCG2EGFRKDR | |
| SCHEMBL7939006 | 0.73 | MAPT (0.44) | ABCG2EGFRKDR | |
| SCHEMBL12813342 | 0.72 | STK17A (0.57) | APPGRM4EGFRKDRMAPK1 | |
| SCHEMBL19787669 | 0.72 | TRPA1 (0.45) | APPGRM4CA12CA1CA2 | |
| SCHEMBL2155009 | 0.71 | ABCG2 (0.53) | APPABCG2EGFRKDRGRM1 | |
| SCHEMBL30270390 | 0.71 | APP (0.55) | APPGRM4CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849734-B2 | Intermediates useful for preparing 4,6-diaminopyrido[5,4-d]pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-01 | — | — | US | disclosed |
| EP-1383770-B1 | METHOD FOR THE PRODUCTION OF 4,6-DIAMINOPYRIMIDO 5,4-D]PYRIMIDINES | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-09-22 | — | — | EP | disclosed |
| US-20040059114-A1 | Intermediates useful for preparing 4,6-diaminopyrido[5,4-d]pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-25 | — | — | US | disclosed |
| US-6680384-B2 | REACTING TETRACHLOROPYRIMIDO(5,4-D)PYRIMIDINE WITH AMINE COMPOUND; REDUCING TO FORM 4,6-DIAMINOPYRIMIDO(5,4-D)PYRIMIDINE COMPOUND | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-01-20 | — | — | US | disclosed |
| US-20020198380-A1 | Process for preparing 4,6-diaminopyrimido[5,4-d]pyrimidines | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198380-A1 | Process for preparing 4,6-diaminopyrimido[5,4-d]pyrimidines | DPYD, DUT, DCTD | APP 3761/4885GRM4 1400/4885CA12 4146/4885 |
| US-20040059114-A1 | Intermediates useful for preparing 4,6-diaminopyrido[5,4-d]pyrimidines | DPYD, DCK, DTYMK | APP 4398/4885GRM4 2235/4885CA12 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.